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In this issue of Cancer Cell, Kikushige et al. report the surprising finding that, in human chronic lymphocytic
leukemia (CLL), hematopoietic stem cells (HSC) aberrantly generate clonal B cells with CLL-like phenotypes,
which implicate HSC in the pathogenesis of this mature lymphoid malignancy and has major implications for
CLL therapies.Blood represents arguably the most
dynamic of human tissues, orchestrating
not only its own complex homeostasis,
but that of virtually every physiological
system. Within this dynamic tissue, nor-
mal hematopoiesis is organized as a cel-
lular hierarchy initiated and maintained
by self-renewing hematopoietic stemcells
(HSC) that give rise to lineage-restricted
progenitors, which eventually produce all
the mature cells of the blood. Cancers
can develop from any of these blood line-
ages, resulting in many different diseases
including myeloproliferative disorders,
acute andchronic leukemias, lymphomas,
and myeloma.
While several myeloproliferative disor-
ders are known to arise at the HSC stage
in hematopoiesis, most other hematologic
malignancies have been linked to later
stages in this hierarchy. For example, ag-
gressive acute leukemias are generally
believed to arise from early progenitors,
with some initial leukemogenic events
occurring in HSC themselves. Further,
the most common class of hematopoietic
malignancies, the mature B cell lym-
phomas and leukemias, are classified ac-
cording to their presumed cell of origin
along the continuum of B cell devel-
opment and differentiation. For these
B cell tumors, relationship to the germinal
center (GC) reaction within secondary
lymphoid organs is central for their classi-
fication as pre-GC, GC, or post-GC neo-
plasms, as these ‘‘mature’’ tumors are
believed to arise from B cells, following
VDJ recombination at immunoglobulin
loci and independent of early hematopoi-
esis and HSC. This consideration has
a major effect on therapeutic targeting,with agents selected for activity against
mature B cells.
Much of the evidence supporting a cell-
of-origin model linking mature B cell
tumors to post-VDJ recombination stages
of lymphoid ontogeny, and with the ger-
minal center reaction, has been indirectly
based on shared phenotypes, including
cell surface markers and capacity for
ongoing somatic hypermutation (Ku¨p-
pers, 2005). Nonetheless, direct evidence
for thismodel comes from the presence of
identical (or nearly identical) VDJ recom-
bination events at the IGH locus in paired
samples from: (1) donors and recipients
involved in inadvertent transmission of
lymphoid malignancies during allogeneic
hematopoietic cell transplantation, (2)
samples at diagnosis and relapse of
mature B cell tumors, (3) samples before
and after histological transformation
from indolent to aggressive lymphomas,
and (4) composite lymphomas occurring
within individual patients with, for ex-
ample, both Hodgkin’s disease and a
non-Hodgkin’s lymphoma (Martinez-Cli-
ment et al., 2010).
This view of mature B cell malignancies
is challenged by the findings reported in
this issue by Kikushige et al. (2011)
through their investigation of human
chronic lymphocytic leukemia (CLL). CLL
is a mature B cell malignancy that is typi-
cally characterized by the accumulation
of clonal mature B cells in the bone
marrow, blood, and lymph nodes that
aberrantly express CD5. In nearly all
cases, CLL is preceded by a preleukemic
monoclonal B cell lymphocytosis (MBL)
(Landgren et al., 2009), though only
a subset of patients with MBL are proneCancer Cell 20to develop CLL over their lifetime (Raws-
tron et al., 2008).While the precise identity
of the normal counterparts of CLL and
MBL remains unclear, most studies
suggest transformation of cells after VDJ
recombination (Chiorazzi and Ferrarini,
2011). In current standard therapy, CLL
is treated with chemotherapeutics active
against B lymphocytes, including DNA-al-
kylating agents and nucleoside inhibitors
such as cyclophosphamide, bendamus-
tine, fludarabine, and pentostatin. In many
cases, CLL is also treatedwithmonoclonal
antibodies including rituximab and ofatu-
mumab, which target CD20 on the surface
of mature B cells (Chiorazzi et al., 2005).
Strikingly, nearly identical VDJ-recom-
bination events can rarely be observed
as independent events in different pa-
tients with CLL and MBL, which can
even include stereotyped or quasi-iden-
tical sequences in the nongermline-en-
coded portion (HCDR3) of rearranged
immunoglobulin genes (Messmer et al.,
2004). Additionally, the usage of immuno-
globulin variable genes is known to be
biased within the B cell receptors of ma-
ture lymphoid tumors, particularly within
CLL and MBL. These observations sug-
gest the presence of selective pressures
that favor specific VDJ clones, including
intrinsic factors such as heritability of
MBL and CLL as well as extrinsic ones
such as undefined autoantigen(s) or path-
ogen(s) capable of stimulating and pro-
moting such B cell clones.
In the current study, Kikushige et al.
(2011) investigate the cellular origin of CLL
by isolating subpopulations and assay-
ing their ability to engraft disease upon
xenotransplantation into immunodeficient, August 16, 2011 ª2011 Elsevier Inc. 135
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Previewsmice. Consistent with prior studies, neither
the CD19+ B cells, nor the CD34+CD38+
CD10+CD19+ pro-B cells stably engrafted
in vivo. The CD34+CD38-(CD90+) fraction,
known to be highly enriched for HSC in
normal marrow, engrafted stably and
gave rise to bilineage lymphoid-myeloid
hematopoiesis. Remarkably, these en-
grafted cells exhibited an increased pro-
portion of polyclonal pro-B cells, and
analysis of VDJ recombinations in the
downstream B cells revealed mono- or oli-
goclonality in a population with features of
MBL, including CD5 expression. Further
examination of the VDJ recombination
events determined that they were different
from those present in the CLL cells. None-
theless, as in human CLL and MBL,
a biased V-gene repertoire was observed
in the lymphoproliferative disorder seen in
these mice, which also shared the ten-
dency for IgVH somatic mutation with the
corresponding CLL. Moreover, the en-
grafted cells showed no evidence of geno-
mic abnormalities present in the original
cancer.
How can all this be put together? It
appears that HSC in CLL are involved in
diseasepathogenesis, serving as aberrant
preleukemic cells that produce an in-
creased number of polyclonal pro-B cells.
The resulting mature B cells are selected,
likely by autoantigen(s), resulting in
mono- or oligoclonal B cell populations.
These clones differ from those present in
the corresponding CLL, perhaps due to
selection by different autoantigen(s) pre-
sent in the human, but not the mouse,
host. But this is not frank CLL, instead
modeling MBL. At some point along the
differentiation pathway, additional geno-
mic abnormalities develop, eventually re-
sulting in the clonal CLL disorder.136 Cancer Cell 20, August 16, 2011 ª2011 EIf this model reflects the biology of the
in situ human disease, one would expect
to detect oligoclonal disease in CLL and/
or MBL patients. Indeed, oligoclonality of
VDJ recombination events is common in
MBL and is also seen in 10%–20% of
CLL cases. However, this model fails to
account for the fact that CLL patients
who achieve molecular remissions, but
ultimately recur, do not relapse with poly-
clonal disease or distinct clones.
The finding of aberrant HSC in CLL rai-
ses the question of what mechanisms
drive this process. Presumably, genetic
and/or epigenetic mutations are present
in these cells and determine their aberrant
behavior. Recently, next generation se-
quencing identified recurrent somatic
mutations, presumably driving transfor-
mation, in CLL (Puente et al., 2011). It
will be of great interest to determine if
these mutations are present in HSC from
CLL patients.
Another implication of these results is
that B cell antigen receptor (BCR) sig-
naling is central to the pathogenesis
of CLL, resulting in the production of
mono- or oligoclonal B cells from poly-
clonal pro-B cells. Once the CLL clone is
established, it is uncertain if continued
signaling is required for the disease.
However, recently, chronic active BCR
signaling has been implicated in the path-
ogenesis of a subtype of diffuse large B
cell lymphoma (Davis et al., 2010). Con-
sistent with this, inhibitors of BCR sig-
naling show activity in several lymphopro-
liferative disorders including CLL.
Nearly all current therapies for CLL,
including rituximab, target the mature B
cell leukemic population; however, it
may be that therapies effective at target-
ing these CLL cells will not affect the pre-lsevier Inc.leukemic HSC. Thus, curative strategies
may need to target not only the frankly
leukemic cells, but also the preleukemic
HSC. How to preferentially target these
preleukemic HSC, as compared to re-
sidual normal HSC, represents a major
challenge that will depend on investiga-
tions into the mechanisms that give rise
to these aberrant cells.REFERENCES
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